Mavoglurant racemate is a research chemical primarily investigated for its potential in treating neurological and psychiatric disorders. It acts as a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), implicated in various brain functions and dysfunctions. Key research focuses on fragile X syndrome, a genetic disorder causing intellectual disability and behavioral challenges, where it modulates glutamate signaling to improve cognitive and behavioral symptoms. Studies also explore its use in addiction treatment to reduce cravings in substance abuse disorders, as well as in anxiety, depression, and levodopa-induced dyskinesias in Parkinson's disease. Clinical efficacy remains under investigation, positioning it as a promising candidate for glutamate dysregulation-related disorders.